"Curse of dimensionality" is the contradiction between mathematical requirement for optimal gene signatures to contain no more than 20-30 genes [5] and biological reality observing10-100 times more differentially expressed genes in cancer tumors. Such short optimal signature are the consequence of the small number of patient samples available in a training set for signature calculation compared to the number of correlated DE genes [6, 7] . The shortage of cancer samples for large signature calculation is so significant that even 10-fold increase in the number of available samples will not yield substantial improvement in predictability of transcriptional signatures.
Introduction
More than 400 FDA approved drugs are currently on the market and were in clinical trials for treatment of common types of cancer in the last five years. Most of these drugs have known mechanism of action and directly target more than 800 proteins in human genome. While not every clinical trial is successful the number of treatment options for cancer is already large and only expected to grow in the future. Thus, the major challenge for modern oncologists is selecting the most effective anti-cancer treatment for a patient from the vast number of approved anti-cancer drugs on the market. The proposed solution for this problem is called personalized medicine -development of approaches for selecting the best treatment for a patient based on drug mechanism of action that most optimally matches the molecular mechanism driving tumor growth.
Gene expression microarray technology is the oldest and most robust method for large scale molecular profiling of cancer patients [1, 2] . While detection technology was improving in last two decades analytical methods were developed for calculating differentially expressed (DE) genes and transcriptional signatures from DE genes from the limited number of patients. These computational approaches yielded a lot of insights into cancer biology [3] but also revealed "curse of dimensionality" of the large scale molecular profiling data [4] .
• Removal of sigmoid colon
• Radiofrequency ablation for two liver lesions 
Gene expression profile
Human U133 Plus 2.0 array were used to process the patients RNA samples. Also, the following instruments were used: Affymetrix Gene Titan instrument for processing the microarrays, GeneChip Hybridization oven 640, two Fluidics Station 450s, and Affymetrix Gene Chip Scanner 3000.
Calculation of differentially expressed genes in patient tumor biopsies
Typically, we were able to measure only one microarray profile for each patient tumor biopsy. Whenever possible we tried to collect syngenic samples to calculate differentially expressed genes. If syngenic sample was not available we used control samples from Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/ geo/). For this, we downloaded from GEO all possible profiles of healthy human tissues that correspond to patient tumor tissue and measuring expression profile on the same microarray chip (HG-U133 plus 2.0 from Affymetrix). The same chip requirement allowed RMA normalization of CEL files for our patient samples together with samples downloaded for GEO.
For patient with colon cancer with metastasis in lung we used syngenic control from other healthy lung. For the patient with liver cancer we used syngenic control from healthy part of the liver. For patient with breast cancer metastasis in lung we used six normal breast tissue samples from GSE3744; for patient with colon cancer metastasis in liver we used 17 control samples from GSE32323; for patient with lung cancer we used 14 normal lung samples from GSE30219. Differentially expressed genes in all cases were calculated in Pathway Studio using unpaired t-test. P-value of differential expression for each probe on the array was possible to calculate only if patient data was normalized on multiple normal control samples from GEO. For these cases only probes with p-value less than 0.05 were used as input for calculation of SNEA regulators. For genes measured by several probes on HG-U133 plus 2.0 chip Pathway Studio selects the probe with best p-value for SNEA.
Pathway Studio: SNEA and cancer pathway reconstruction
We used Pathway Studio version 9 with knowledge base containing data extracted by Elsevier natural language processing (NLP) technology from all Pubmed abstracts and from more than 2,000,000 full-text articles published in about 1,200 biomedical journals [14] . Elsevier NLP extracts various types of biological interactions for Pathway Studio database. In order to identify upstream expression regulators by SNEA we used Expression and Promoter Binding regulatory interactions. These relation types are included in the option "Expression targets" in Pathway Studio menu for SNEA. Most regulators identified by this SNEA option are transcription factors, receptors, secreted hormones and extracellular matrix proteins. Typically, we were able to map about 30% of all SNEA regulators identified from patient expression profile on the signaling and cell process pathways that already existed in Pathway Studio, e.g. pathways for cell cycle, apoptosis regulation, DNA repair and chromatin remodeling. For purpose of building additional cancer pathways we connected remaining regulators that have not been mapped on existing pathways, with physical interactions in Pathway Studio database (i.e., Binding, Direct Regulation and Protein Modification) in order to find regulators involved in common pathway. Functionally-related a tumor. A set of ten high-level biological processes responsible for cancer progression is known as hallmarks was suggested [13] . Each cancer hallmark can be facilitated by several alternative mechanisms described in the literature but in one given patient only one of these alternatives is realized by the tumor at one time. Because the same biological mechanism may still involve different proteins in different tissues several hundred pathways have to be built in order to create a comprehensive collection of cancer hallmarks mechanisms in different tissues. Yet, only a handful of these pathways will be activated in a single patient.
In this article we describe workflow for personalized medicine that uses gene expression profile of patient tumor to identify major expression regulators which transcriptional activity is significantly altered in the tumor according to SNEA. Using most significant expression regulators identified from five transcriptional tumor profiles of three cancer patients we have constructed the library of cancer hallmark pathways. All pathways are based on translational data from scientific literature that studied cancer cell lines or cancer in animal models. These pathways can explain activity of about 60% expression regulators in our patients. We assert that pathways enriched with major SNEA regulators have altered activity in the tumor and therefore should be used to select drugs for personalized treatment. We validated our approach by selecting drugs inhibiting the activity of identified pathways. Even though sometimes it was not possible to find drug that could directly inhibit expression regulators found by SNEA drugs selected based on upstream pathway information prolonged patient survival beyond Overall Survival estimates based on standard of care treatment. This article focuses on describing pathways identified by our approach and used for treatment selection. 
Materials & Methods

Patients
Pathway Studio: drug selection
We used relations depicting drug effects extracted by Elsevier NLP ChemEffect cartridge [15] in order to find drugs for patient treatment. Our drug selection was done by following progressive steps. First, we attempted to find FDA-approved anti-cancer drugs inhibiting activated expression regulators that have been identified by SNEA. For this, we looked for drugs linked to SNEA regulators by Direct Regulation with Table 1 : List of cancer hallmark pathways with supporting literature. PMID -Pubmed ID of the article used for pathway reconstruction. Cancer hallmark processes are borrowed from [13] .
Cancer Hallmark
Pathway Name Number of entities trial of Sorafenib + Voronistat combination at the Massey Cancer Center in Richmond, Virginia after approval by its ethics committee.
Number of relations Publication PMIDs
Results
Pathway collection for analysis of cancer patients
We have constructed 49 pathways containing 2,779 proteins (Table  1) . Pathways represent different mechanisms for ten cancer hallmark processes [13] . Pathways for cell cycle, apoptosis, DNA repair, Regulation Effect negative. As additional selection criteria we preferred the drugs with demonstrated efficacy against the type of cancer developed in the analyzed patient. We could check known drug efficacy in Pathway Studio by looking up the relations between the drug and the right type of cancer with Regulation relation with Effect negative.
Statement of ethics
All but one patient were treated with FDA approved drugs prescribed by physician. Liver cancer patient was placed on a clinical Table 3 ). Figure 1D : Depicts EGFR activation by apoptotic clearance. This pathway resembles the wound healing pathway and was found activated in all three patients ( Table 3) . "Find-me" signals from apoptotic debris (LPC) activatemacrophages growth factors to secrete growth factors. LPC is also converted into LPA by secreted lysophospholipase D. LPA activates LPA receptor on the surface of epithelial cells that in-turn activate NF-kappa-B transcription factor in order to express and secrete matrix metalloproteases (e.g. ADAM17). These matrix metalloproteases convert growth factors secreted by macrophages into activated form and induce cell proliferation. Depiction of cells from adaptive immune response secreting EGFR ligands is based on the relatively new report [21] from 2013. contribute to tumor-induced inflammation. We did not consider these proteins as therapeutic targets for our patients and therefore we do not describe them in this paper.
Patient tumor
Identification of pathways with altered activity in cancer patients
Top 100 SNEA regulators with p-value less than 0.05 were 
2A
2B
Figure 2: Additional pathways showing SNEA expression regulators identified in cancer patients by highlight. Different highlight colors correspond to different patients used in this study: orange -first lung cancer patient; green -second lung cancer patient; red -liver cancer patient; figure legend is shown on figure 1A . All pathways were enriched with major expression regulators identified by SNEA with p-value smaller than 0.05 according to Fisher exact test. driven by hypoxia via activation of HIF1 transcription factor, by thrombosis via activation of thrombin (F2), and by oxidized LDL. EGFR activation was due to macrophages activation releasing of oncostatin and HB-EGF. Macrophages were activated mainly by apoptotic debris clearance and by oxidized LDL. Apoptotic debris clearance is also known to induce HB-EGF conversion into active form via lysophosphatidic acid accumulation [16] . Tumor invasiveness was driven by epithelial-to-mesenchymal transition (EMT) promoted by hormones PDGF, IGF, TGFB; extracellular matrix proteins CTGF and SPARC; and transcription factor KLF5. Tumor proliferation was sustained through activation of EGFR. Observed activation of components of dREAM complex (LIN9, MYBL2, E2F3) responsible for transition between quiescent and proliferative states probably criteria to select activated pathways: the ligand or corresponding receptor initiating the pathway must be on the list of major regulators calculated by SNEA. The results for each patient are shown in table 2 and figure 2. We found that patient's tumor profiles were more similar on the level of activated pathways then on the level of individual SNEA regulators. Table 3 lists 26 pathways that were found activated in all three patients. Patient differences on the level of SNEA regulators were most likely due to tissue specificity of gene expression since two patients with lung cancer had 72% of SNEA regulators in common while only 10% of regulators were common in patients with cancers from different tissues. Table 4 lists most common SNEA regulators found among three patients. In summary, we found that angiogenesis in patients was One of these inhibitors Palbociclib (Ibrance) is also known to indirectly inhibit FoxM1 transcription factor important not only for cell proliferation but also for invasive tumor phenotype through activating epithelial-to-mesenchymal transition. reflects tumor heterogeneity with part of the tumor being quiescent and not going through angiogenic switch [17] .
Pathway Cancer hallmark
F2->angiogenesis Angiogenesis
VEGFR->endothelial proliferation Angiogenesis
N1->N2 neutrophil polarization
Treatment selection for patients using pathway analysis Figure 3 shows several examples of finding the drugs for a patient using pathway analysis in combination with ChemEffect knowledgebase available for Pathway Studio. ChemEffect contains regulatory effects for drugs found in scientific literature [15] . The main criteria for drug selection was that the drug had to be approved by FDA for cancer treatment or at very least allowed for cancer clinical trial. We then searched for drugs that had efficacy against pathways found to be activated in patient tumor according to SNEA analysis. If pathway did not have any druggable components we resorted to FDA-approved drugs that showed efficacy toward cell process that was found to be activated in patient tumor, e.g. epithelial-tomesenchymal transition (EMT) in figure 3B . If several drugs satisfied above criteria we selected a drug which efficacy against the same type of tumor as in patient had the most support in the literature, i.e., had the biggest number of articles and clinical trials describing drug efficacy towards the appropriate cancer.
Discussion
Novel approach for selection of personalized cancer therapy
We describe the approach for analysis of cancer tumor that enables rational therapy design based on molecular mechanism responsible for tumor malignancy in a patient. Our approach consists of identification of major regulators responsible for differential gene expression in patient tumor and subsequent identification of cancer hallmark pathways enriched with the regulators. To enable the workflow we constructed 49 pathways in Pathway Studio depicting various mechanisms of cancer development reported in scientific literature. While the underlying technology can be and should be optimized further our goal was to achieve validation of the approach in clinical settings. The drugs rationally selected based on pathway analysis prolonged patient survival beyond Overall Survival estimates based on standard of care treatment. Our study demonstrates that the analysis of individual tumor sample compared to multiple normal controls is sufficient to produce biologically relevant results that can be further used as basis for clinical decision to select personalized therapeutic intervention. The biological relevance of individual patient tumor analysis is confirmed by finding canonical text-book pathways activated in the tumor.
We believe that further improvements in technology will enable even more precise treatments for cancer patients. One major improvement can come from the manual curation of the Expression regulatory relations used by SNEA to calculate major regulators. The curation can not only reduce the number of false positives but also annotate relations with correct effect sign (positive or negative) and with tissue-specific information. The curation of effect sign will allow calculation of the correct activation score for each SNEA regulator based on the concordance between the directions of expression change of each target and effect of the regulation event (i.e., transcription activation or repression). Such activation score can be used for Gene Set Enrichment analysis (GSEA) of cancer pathways [9, 18] instead of overlap Fisher's Exact test that was used in this article. Annotation with tissue specificity should also improve accuracy of SNEA p-value calculation that is used to determine regulator significance. Our cancer pathway collection can be also expanded since it does not yet contain pathway for all cancer hallmarks [13] . We have only built pathways containing SNEA regulators in order to interpret microarray data from our patients.
The fact that all our patients outlived the life expectancy from the current standard of care suggests that individualized therapy selected based on molecular profile of the tumor can be better alternative to one drug fits all patients model suggested by the standard of care approach. We also argue that selection of patients for clinical trials based on the molecular profile of the tumor using our approach can significantly improve chances for the trial success.
Cellular mechanisms found in patients with advanced cancers
Our approach identifies cell processes driving cancer progression in a patient. These processes can be used for drug selection. All three patients analyzed for this article had advanced cancers characterized by metastasis and rapid tumor growth according to clinical parameters. Consequently, we have identified processes activated in these patients that confer advanced tumorigenesis. Several pathways were built by translation of data obtained from in vitro studies for patient data. Identification of SNEA regulators from these translational pathways in patient tumors further confirmed that these in vitro findings were applicable in clinics. For example, pathway "EGFR activation by apoptotic clearance" was built by combining the established role of lysophosphatidic acid (LPA) in the activation of EGFR signaling in cancer [19, 20] with very recent in vitro studies showing that tumorassociated macrophages is the source of HB-EGF, which is EGFR ligand that is activated by LPA [21] . We hypothesize that tumorassociated macrophages are activated by apoptotic debris that is in abundance inside the tumor. Lysophosphatidylcholine (LPC) is the major "Find-me" signal attracting macrophages to apoptotic debris [22, 23] and at the same time is precursor of LPA. Thus, dying tumor cells activate EGFR pathway through macrophage activation to sustain tumor growth. "EGFR activation by apoptotic clearance" pathway resembles wound healing mechanism that was adapted for tumor growth.
We observed thrombin activation in all three patients (Table 3 and  Table 4 ). This further supports a role of platelet-induced coagulation in tumor progression [24] [25] [26] . Thrombin can promote several cancer hallmarks. It sustains tumor growth via activation of oncogenic AP-1transription factor. Thrombin activates HIF1A transcription factor [27] which mimics hypoxic state and leads to angiogenesis by activating endothelial cells and to macrophage polarization enabling tumor to avoid immune destruction [28] . Thrombin also activates ROCK kinase causing cytoskeleton reorganization. Cytoskeleton reorganization in endothelial cells promotes their migration and therefore further promotes angiogenesis and vascular permeability; on the other hand activation of cytoskeleton reorganization in tumor cells promotes its invasiveness [29, 30] .
We developed "TGF-beta loop" pathway that depicts mechanism of epithelial-to-mesenchymal transition induced by TGF-β mediates. TGF-β is potent autocrine inducer of epithelial-to-mesenchymal transition in the presence of growth factors [30] . While the autocrine secretion of TGF-β in tumors was described previously [31] as TGF-β->SNAIL->SMAD3/4-> TGF-β loop [32] [33] [34] [35] [36] we were able to infer the existence of multiple secondary loops activating latent TGF-β activation from existing literature. These secondary loops are mediated by RUNX transcription factors [37] and their dimerization with ETS1/2 on target gene promoters [38] [39] [40] . RUNX induces expression of TGF-β receptors [38] , while ETS1 activates expression of integrinbeta 6 [41] , CD44 [42] and FLT1 [43] . AlphaVbeta6 integrin complex binds and activates latent TGF-β [44] , CD44 binds TGF-β receptors [45] and activates latent TGF-β [46] , FLT1 mediates survival in post-EMT cancer cells [47] . Both RUNX and ETS1 activate expression of MMP9 [48, 49] , which cleaves and activates latent TGF-β [50, 51] . RUNX transcription factor was shown to be activated in metastatic breast cancer [48] and in thyroid carcinoma [49] .
We found that the similarity between patients was higher on pathway level than on the level of individual expression activators. Figure 2 depicts pathways identified in different patients with their respective expression activators highlighted by one color corresponding to each patient. Thus, even if patients had different set of expression regulators they still pointed to the same pathway suggesting that the same pathway can be activated in individual tumors albeit different mechanisms. Similarity of tumors on pathway level may be explained by the fact that all patients had metastatic cancer. Because we selected the same treatments for patients with similar activated pathways our finding also suggests that patient with similar activated pathways can have similar clinical outcome despite the difference in the underlying molecular mechanism for pathway activation in their tumors.
Drug availability to target patient pathways
The most logical choice of anti-cancer therapy is a drug inhibiting major expression regulators activated in patient tumor. Our experience with three patients revealed that many regulators, especially transcription factors, do not have either direct or indirect FDA approved inhibitors, while many existing FDA-approved inhibitors found in Pathway Studio are not approved for cancer treatment by FDA. Therefore for most patients we resorted to experimental drugs that have shown some efficacy against appropriate type of cancer and also could inhibit the cell process indicated by pathway analysis (Table 3) . Noteworthy, in cases when FDA-approved drugs were not available for SNEA regulators we always were able to find plant extracts with reported inhibitory properties.
